SOPH — SOPHiA GENETICS Reports Third‑Quarter 2026 Results; Announces ARC Regulatory Collaboration on EU Clinical‑trial Assay Support

What happened

SOPHiA GENETICS (ticker: SOPH) published issuer materials on Nov. 3, 2026 reporting financial results for the third quarter ended Sept. 30, 2026 (company IR item: https://ir.sophiagenetics.com/2026-11-03-SOPHiA-GENETICS-Reports-Third-Quarter-2026-Results). In a separate company release the firm announced a collaboration with ARC Regulatory to support EU clinical‑trial assay development (news link: https://www.sophiagenetics.com/news/arc-regulatory-collaboration). Both items appear in the supplied news market data.

Sources: S1 · S3

Why it matters

An issuer‑level Q3 results release is a primary company catalyst that commonly drives headline‑driven share and options activity; a collaboration tied to clinical‑trial assay development is a strategic operating update for a diagnostics/precision‑medicine company. Traders should treat these as company‑specific catalysts until official line‑item figures and any management commentary are read.

Sources: S1 · S3

What to watch / source

Open SOPHiA GENETICS’ investor‑relations release to confirm reported revenue, EPS and any guidance or reconciliations (IR link above). The supplied market data do not include the numeric Q3 metrics; verify line‑item figures and management commentary before sizing event trades.

Sources: S4 · S2

What remains uncertain

• Supplied market data confirm the Q3 report and the ARC Regulatory collaboration but do not include line‑item financial metrics (revenue, EPS) or any guidance—open the company IR/press releases to get the full figures and reconcile totals.